RedHill Announces Positive Obesity and Diabetes Results with Opaganib
August 19, 2024 / Obesity Treatment / Weight Loss Therapy / RedHill Biopharma
RedHill Biopharma’s opaganib shows promising results in reducing weight gain and improving glucose tolerance in obesity and diabetes models, positioning it as a potential therapy for obesity-related disorders through sphingosine kinase-2 (SPHK2) inhibition.
Association between systemic immune-inflammation index and cardiovascular-kidney-metabolic syndrome
August 19, 2024 / SII / Cardiovascular-Kidney-Metabolic Syndrome / CKM Risk Factor / CKM Syndrome Biomarkers
The study found a positive correlation between the Systemic Immune-Inflammation Index (SII) and the risk of Cardiovascular-Kidney-Metabolic (CKM) Syndrome, with higher SII levels associated with increased CKM risk and its individual components.
Obesity-induced adipose inflammation boosts extracellular vesicle secretion
August 19, 2024 / Metabolic Disorders / Adipose Tissue Communication
Obesity-induced inflammation in adipose tissue significantly increases the secretion of extracellular vesicles, particularly from visceral fat, which may contribute to metabolic disorders and elevated plasma triglyceride levels.
Innovative Therapies Aim To Combat Metabolic Syndrome
August 12, 2024 / Metabolic Disorders / Immune Cell Dysfunction / Lipid Metabolism
Researchers are exploring neuromodulation, a technique involving nerve stimulation, as a promising treatment for metabolic syndrome. This innovative approach could help manage obesity, diabetes, and inflammation by influencing brain signals and reducing appetite.
Study reveals new insights into urea cycle’s role in fatty liver disease
August 19, 2024 / Urea Cycle / Fatty Liver Disease / MASLD Treatment / MASH Treatment
New research reveals that defects in the urea cycle contribute to fatty liver disease by disrupting energy metabolism, leading to excessive fat storage in the liver. These findings may lead to new treatments for metabolic dysfunction-associated liver diseases.
Beyond the scale: The hidden threat of normal-weight obesity
August 18, 2024 / Obesity / Metabolic Syndrome / Cardiovascular Risks
Normal-weight obesity, where individuals have a healthy BMI but unhealthy fat distribution, poses significant health risks like metabolic syndrome and cardiovascular issues. This condition often goes unnoticed, highlighting the need for comprehensive health assessments beyond weight.
Rare diseases point to connections between metabolism and immunity
August 17, 2024 / Metabolism / Immunometabolism / T Cell Function / Rare Disease Therapy
A study reveals a significant overlap between genes responsible for inborn errors of metabolism and immunity, suggesting these rare diseases are interconnected, potentially leading to new treatments targeting immune and metabolic disorders.
Weight gain leads to greater adverse metabolic responses in South Asian compared with white European men: the GlasVEGAS study
August 16, 2024 / Metabolic Risk / Insulin Sensitivity / Weight Gain / Type 2 Diabetes
South Asian men experience significantly greater adverse metabolic effects from weight gain compared to white European men, including a larger decrease in insulin sensitivity and differences in adipocyte morphology, contributing to higher type 2 diabetes risk.
Center for Weight Loss & Surgery of Oswego Health Medical Practice Achieves Accreditation from the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program®
August 16, 2024 / Bariatric Surgery / Obesity Treatment / Oswego Health / Metabolic Surgery
The Center for Weight Loss & Surgery at Oswego Health has been reaccredited as a Comprehensive Center by the MBSAQIP®, ensuring high standards of patient safety and quality care for obesity and metabolic surgery patients.
Understanding Silent Brain Strokes And Metabolic Syndrome
August 16, 2024 / Silent Brain Strokes / Metabolic Syndrome / Blood Pressure Management
Silent brain strokes and metabolic syndrome are significant but often unnoticed health risks. Silent strokes can lead to cognitive decline, while metabolic syndrome increases the risk of heart disease and diabetes. Both conditions can be mitigated through lifestyle changes and regular monitoring.
New Class of Beige Fat Cells Linked to a Leaner Physique and Better Metabolic Health
August 15, 2024 / Beige Fat Cells / Obesity / Metabolic Health
Researchers identified a new class of beige fat cells that promote heat production through futile cycles, potentially aiding in obesity and metabolic disorder prevention by improving energy metabolism.
3D body scanner with AI predicts metabolic syndrome risk
August 15, 2024 / 3D Body Scanner / AI / Metabolic Syndrome
Mayo Clinic researchers developed an AI-powered 3D body scanner that accurately predicts metabolic syndrome risk by assessing body volume in key areas, offering a more precise alternative to BMI and waist-to-hip ratio for early detection.
KERI advances neuromodulation technology for appetite suppression in obesity treatment
August 14, 2024 / Obesity / Neuromodulation / Non-invasive Treatment / Metabolic Syndrome
KERI’s neuromodulation technology, using transcranial random noise stimulation (tRNS) to suppress appetite, shows promise as a non-invasive obesity treatment, targeting the brain’s dorsolateral prefrontal cortex to manage metabolic syndrome without chemical side effects.
NeuroBo concludes subject enrolment in SAD portion of obesity treatment trial
August 14, 2024 / Obesity Treatment / NeuroBo DA-1726 Trial / Clinical Trial / GLP-1 Receptor
NeuroBo Pharmaceuticals completed subject enrollment in the Phase I trial of DA-1726, a dual agonist for obesity treatment. The trial will assess safety, tolerability, and pharmacokinetics, with top-line data expected in late 2024.
Early life exposure to common chemical permanently disrupts gut microbiome
August 14, 2024 / Efruxifermin Phase 3 Trials / MASLD Treatment / MASH Fibrosis Reduction / Fatty Liver Disease
Akero Therapeutics is enrolling participants in three Phase 3 trials for efruxifermin, an injectable therapy targeting metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis (MASH), aimed at reducing liver fat and fibrosis.
Research shows our bodies go through rapid changes in our 40s and our 60s
August 14, 2024 / Metabolic Changes Aging / Metabolism / Aging / Carbohydrate
A study published in Nature Aging reveals that significant metabolic changes occur in our 40s and 60s, affecting lipid and carbohydrate metabolism, which may impact cardiovascular health and immune function.
Rivus Pharmaceuticals’ Phase 2a HuMAIN Trial Meets Primary Endpoint of Weight Loss and Secondary Endpoints in Patients with Obesity-Related Heart Failure
August 13, 2024 / Metabolic Accelerator / Obesity / Heart Failure / Weight Loss / Rivus Pharma / Metabolic Health
Rivus Pharmaceuticals’ Phase 2a HuMAIN trial demonstrated significant weight loss and improved metabolic outcomes in patients with obesity-related heart failure (HFpEF) using HU6, a novel Controlled Metabolic Accelerator (CMA), which preserves muscle mass while reducing fat.
PathAI Announces Launch of AI-based Measurement of Metabolic Dysfunction-Associated Steatohepatitis (“AIM-MASH”) on the AISight Image Management System
August 13, 2024 / PathAI / AIM-MASH / AISight Image Managemnet System / AI / Metabolic Liver Diease
PathAI has launched AIM-MASH on the AISight Image Management System, an AI-based tool designed to improve the accuracy, reproducibility, and scalability of MASH assessments in liver biopsies, aiding pathologists in diagnosing and managing metabolic dysfunction-associated steatohepatitis.
Scientists elucidate age and gender disparities in cardiometabolic phenotypes and lipidomic signatures
August 13, 2024 / Cardiometabolic Risk / Lipidomic Profiles / Metabolic Disease Management
A study reveals that age and gender significantly influence cardiometabolic risk factors and lipid profiles, with variations in cholesterol and triglyceride levels. These findings underscore the need for age-specific, gender-tailored strategies in managing metabolic diseases.